Argentina caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The archive — 2024
Page 12 of 68 of this archive, newest first.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 12-day notice: how a compounding wind-down works in Canada
The document is four pages. Three of them are about dates.
The supplement trade found this drug class quickly, and the citations did not improve
A survey of what the meta-analyses support, with the populations named.
Two sessions a week, and the evidence behind the prescription
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
Units, millilitres, milligrams: three scales on one small object
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves…
Homopeptide declines, for the 8th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
India declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The quiet end of Halvard & Pike Apothecary of Portland, Maine
A proper account of an operation that existed, and of what closing it cost.
Turkey pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What we would need to randomise to answer this properly
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
Nigeria caps tirzepatide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A shortage listing ends. 5 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Discontinuation rates, read honestly
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What Janoshik would need in order to certify sterility, and why it does not
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Brazil declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The relabeller trading as Vantris Bio closes after 8 years
A proper account of an operation that existed, and of what closing it cost.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The retest date and the expiry date are not the same document
We asked twenty companies three questions about stability data and print every answer, refusal and non-response.
Non-responders, and the honest state of the evidence about them
A catalogue of open questions, with an assessment of how likely each is to be resolved.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to India after 14 consecutive customs detentions
The route did not close because of a rule about peptides.
PIONEER 6 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Two sessions a week, and the evidence behind the prescription
The recommendation survives scrutiny. The reasoning offered for it frequently does not.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The Netherlands declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.